{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:19:50Z","timestamp":1789957190480,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00987","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T19:10:13Z","timestamp":1593198613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Fabian","family":"Weykamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Seidensaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sati","family":"Akbaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan E.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Weichselbaum","year":"1995","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/cncr.21305","article-title":"Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas MD Anderson Cancer Center and assessment of prognostic factors","volume":"104","author":"Hanrahan","year":"2005","journal-title":"Cancer Interdisc Int J Am Cancer Soc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radiother Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.breast.2018.09.006","article-title":"Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy","volume":"42","author":"Onal","year":"2018","journal-title":"Breast"},{"key":"B6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cncr.29134","article-title":"The rise in metastasectomy across cancer types over the past decade","volume":"121","author":"Bartlett","year":"2015","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2016.11.003","article-title":"The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: what do we know and where are we going?","volume":"52","author":"Hong","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","article-title":"Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases\u2014a pooled analysis of the German working group \u201cstereotactic radiotherapy\u201d","volume":"97","author":"Rieber","year":"2016","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","article-title":"Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy","volume":"190","author":"Sterzing","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase ii, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer Interdisc Int J Am Cancer Soc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The Dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.21037\/jtd.2017.03.106","article-title":"Prognostic impact of M descriptors of the 8th edition of TNM classification of lung cancer","volume":"9","author":"Dias","year":"2017","journal-title":"J Thorac Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.breast.2017.10.011","article-title":"Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: an analysis based on SEER 18 database","volume":"37","author":"Wang","year":"2018","journal-title":"Breast"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/tbj.13435","article-title":"Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: a commentary on a survey of Canadian Medical Oncologists","volume":"25","author":"Donovan","year":"2019","journal-title":"Breast J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3857\/roj.2015.33.4.301","article-title":"Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy","volume":"33","author":"Yoo","year":"2015","journal-title":"Radiat Oncol J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"key":"B21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.rpor.2016.07.008","article-title":"The role of SBRT in oligometastatic patients with liver metastases from breast cancer","volume":"22","author":"Scorsetti","year":"2017","journal-title":"Rep Pract Oncol Radiother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","volume-title":"S3-Leitlinie \u201cInterdisziplin\u00e4re Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms\u201d. Forum","author":"W\u00f6ckel","year":"2019"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000489329","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018","volume":"13","author":"Liedtke","year":"2018","journal-title":"Breast Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000489331","article-title":"AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2018","volume":"13","author":"Thill","year":"2018","journal-title":"Breast Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12282-018-0921-1","article-title":"Oligometastatic breast cancer","volume":"26","author":"Kwapisz","year":"2019","journal-title":"Breast Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","article-title":"Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy","volume":"115","author":"Milano","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2019","journal-title":"Breast"},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?","volume":"124","author":"Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease \u2013 influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0195149","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PloS ONE"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3389\/fimmu.2017.01476","article-title":"Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer","volume":"8","author":"Muraro","year":"2017","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S1447","DOI":"10.21037\/jtd.2018.05.107","article-title":"Combining immunotherapy and radiotherapy in lung cancer","volume":"10","author":"Bhalla","year":"2018","journal-title":"J Thorac Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non\u2013small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e4103","DOI":"10.7759\/cureus.4103","article-title":"Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases","volume":"11","author":"Dagoglu","year":"2019","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1055","DOI":"10.1634\/theoncologist.2019-0197","article-title":"Programmed cell death ligand 1 in breast cancer: technical aspects, prognostic implications, and predictive value","volume":"24","author":"Miglietta","year":"2019","journal-title":"Oncologist"},{"key":"B39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/j.cllc.2017.04.002","article-title":"Local therapy for oligoprogressive disease in patients with advanced stage non\u2013small-cell lung cancer harboring epidermal growth factor receptor mutation","volume":"18","author":"Qiu","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"100708","DOI":"10.18632\/oncotarget.20022","article-title":"Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis","volume":"8","author":"Santini","year":"2017","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1367159","DOI":"10.1155\/2017\/1367159","article-title":"Patterns of progression in metastatic estrogen receptor positive breast cancer: an argument for local therapy","volume":"2017","author":"Kelly","year":"2017","journal-title":"Int J Breast Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/annonc\/mdf232","article-title":"High-dose chemotherapy for breast cancer: any use for it?","volume":"13","author":"Gianni","year":"2002","journal-title":"Ann Oncol"},{"key":"B47","unstructured":"Strahlentherapie bei Patientinnen mit oligometastasiertem Mammakarzinom91826\n            KrugD\n            FabianA\n            PyschnyF\n            BlanckO\n            DellasK\n            MaassN\n          Der Gyn\u00e4kol522019"},{"key":"B48","doi-asserted-by":"publisher","first-page":"TPS1117","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS1117","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical ablation for newly oligometastatic breast cancer (NCT02364557)","volume":"37","author":"Chmura","year":"2019","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2018.06.011","article-title":"Stereotactic radiotherapy in metastatic breast cancer","volume":"41","author":"Possanzini","year":"2018","journal-title":"Breast"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/j.ijrobp.2010.10.074","article-title":"Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage Non-small cell lung cancer","volume":"81","author":"Sher","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fonc.2013.00077","article-title":"Stereotactic radiosurgery and stereotactic body radiation therapy cost-effectiveness results","volume":"3","author":"Bijlani","year":"2013","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T19:10:15Z","timestamp":1593198615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":51,"alternative-id":["10.3389\/fonc.2020.00987"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00987","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"article-number":"987"}}